EU's CHMP rejects PTC's Duchenne drug
This article was originally published in Scrip
Executive Summary
PTC Therapeutics' admittedly faint hopes for early marketing of the investigational drug for the rare genetic disorder Duchenne muscular dystrophy Translarna (ataluren; PTC124) in the EU have been dashed by the CHMP.